Avistron Chemistry Services ::: Drug discovery products, molecules and contract services

	Back to news list >>
	29/04/2015
	Avistron offers MCC950 - A potent & selective NLRP3 inflammasome inhibitor

	In a recent study published in the world's leading preclinical medical Journal Nature Medicine by an international research team led by scientists from the University of Queensland Australia and Trinity College Dublin, MCC950 was found to block a key driver of inflammatory diseases. The finding could inspire the development of non-invasive treatments for the inflammatory diseases such as arthritis, multiple sclerosis and Muckle-Wells syndrome. Avistron is pleased to now be able to offer the compound MCC950 from stock.

>> Existing Customer Log On

>> New Customer

If you can't find what you're looking for on our website, then please contact us and let us guide you to the solution you're searching for!

>> Registration Form

Register on line to see further information on our products and services and to join our mailing list.

Search our current catalogue via Structure, ID, Keyword or CAS number.